News,  Publications

News


4 June 2021

The Olivia Newton John Cancer Research Institute (ONJCRI, https://www.onjcri.org.au) and Sanoosa are pleased to announce their partnership on a new drug discovery program. Together, they will engage in the discovery and design of novel small molecules for inhibiting the binding of IL-11 to its receptor. With the vast know-how in computational discovery of Sanoosa and ONJCRI’s deep experience in cancer research and the combined experience of the teams in pre-clinical drug discovery and development, the partnership aims to bringing a novel small molecule to IND status.

 


14 May 2021

Epichem (https://epichem.com.au) and Sanoosa team up against RAS-related Tumors. 


RAS is the most frequently mutated gene family in cancers, and investigators have sought an effective RAS inhibitor for more than three decades. RAS is mutated in a way that causes loss of its GTPase activity, thereby activating downstream effectors of RAS pathways. 

Novel, Small Molecule Therapeutic for Oncology.


Epichem, Australia’s premiere contract medicinal chemistry company has partnered with Sanoosa, a computational drug discovery company to develop a novel hit series active and selective in a KRAS synthetic lethal phenotypic screening module. 


Please follow this link to find out further details of the collaboration. 

 


11 May 2021

Peptris (https://peptris.com) and Sanoosa are pleased to announce their partnership on a new drug discovery program. Together, they will engage in the discovery and design of novel small molecule inhibitors for an undisclosed inflammation target. With the vast experience in computational discovery of Sanoosa and the novel AI platform of Peptris, pepAI, and the combined experience of the teams in pre-clinical drug discovery and development, the partnership is committed to bringing a novel small molecule to IND status in record time.


Mr. Venkatsubramanian Narayanan, CEO and Co-founder of Peptris said: "This is a unique collaboration that synergises two powerful computational approaches and aims to deliver a candidate drug in record time. This can pave the way for more partnerships leveraging the strengths of both teams to create novel therapies in the inflammation and oncology space”. 


Sanoosa’s founders Dr. Wolfgang Kissel and Dr. Herbert Treutlein commented: “We are looking forward to working with Peptris on this exciting project. Complementing each other’s strengths is core to our strategy and will show that small companies can achieve big things. Our joint focus on the crossroads of Inflammation and Cancer enables us to contribute to therapies that are most needed.”


About Peptris

Peptris is an AI/ML company that is committed to improving efficiencies in drug discovery and accelerating development. Peptris has created a versatile AI platform that can accurately predict Protein-Small Molecule interactions and resulting biological activity across a wide range of protein targets and molecules. Peptris is actively engaged with biotech and pharma partners to leverage its pepAI platform to help discover potent molecules faster. Peptris is also working on a proprietary target to therapy pipeline to discover novel targets and therapies for oncology and inflammation. You can view more information atwww.peptris.com


28 August 2020

Sanoosa and ViroCarb (https://virocarb.com) are collaborating in a new drug discovery partnership. Together, both parties engage in the discovery and design of novel small molecules for inhibitors that function as novel antiviral agents.


Both companies will apply their special capabilities to bring this challenging project. Sanoosa will apply its proprietary drug discovery platform to model specific target structures and for the discovery and design of small molecule viral inhibitors. ViroCarb will use its expertise in viral biology, biological testing and pre-clinical development to bring the new molecules to IND status.


17 August 2020

Sanoosa and Bipharm (https://bipharm.co) are collaborating in a new drug discovery partnership. Both parties have agreed to engage in the discovery and design of novel small molecules for protein-protein interaction inhibitors in oncology.


Both companies will apply their special capabilities to bring this challenging project. Sanoosa will apply its proprietary drug discovery platform for the discovery and design of small molecule protein-protein interaction inhibitors. Bipharm will use its experience in biological testing and pre-clinical development in oncology to bring the new molecules to IND status.


1 May 2020

Sanoosa will be present at the Bio 2020 International Convention in San Diego, CA, on June 8-12, 2020.  Because of the COVID-19 pandemic the convention is held in digital form and is renamed BIO Digital. Sanoosa’s proprietary small molecule drug discovery & design platform creates significant productivity gains in early drug discovery. Our technology comprises agile process structures and is focused on difficult to drug disease targets, like protein-protein interactions and protein surfaces. Sanoosa’s Founders will meet interested partners and potential collaborators at several one-on-one online meetings.


18 April 2020

Sanoosa will be present at the BIO Korea 2020 Convention on May 18-22, 2020.  Because of the COVID-19 pandemic the convention is held in digital form and is renamed BIO Digital. Sanoosa’s proprietary small molecule drug discovery & design platform creates significant productivity gains in early drug discovery. Our technology comprises agile process structures and is focused on difficult to drug disease targets, like protein-protein interactions and protein surfaces. Sanoosa’s Founders will meet interested partners and potential collaborators at several one-on-one online meetings.


15 April 2020

Sanoosa will be present at the COVID-19 Virtual Partnering Event on May 4-6, 2020. Sanoosa’s proprietary small molecule drug discovery & design platform creates significant productivity gains in early drug discovery. Our technology comprises agile process structures and is focused on difficult to drug disease targets, like protein-protein interactions and protein surfaces.


With the increasing emergence of the COVID-19 pandemic we are obliged to contribute with our work to find novel solutions to fight this virus and the disease. With our in-silico platform we can find novel small molecules that aim at preventing virus infection and that keep the virus related diseases in check. Our experience in protein-protein interaction inhibition can be fully applied to block Sars-CoV-2 to interact with human host cells and for inhibiting the strong inflammatory reactions in various stages of the disease.  


We  seek to partner with companies where both parties complement their capabilities to generate novel small molecule inhibitors for SARS-CoV-2. In a joint project we can further design the molecules to enter pre-clinical / clinical studies. Sanoosa’s Founders will meet interested partners and potential collaborators at several one-on-one online meetings.


18 May 2019

Sanoosa will be present at the Bio 2019 International Convention in Philadelphia, PA, on June 8-12, 2019.  Sanoosa’s proprietary small molecule drug discovery & design platform creates significant productivity gains in early drug discovery. Our technology comprises agile process structures and is focused on difficult to drug disease targets, like protein-protein interactions and protein surfaces. Sanoosa’s Founders will meet interested partners and potential collaborators at several one-on-one meetings in Philadelphia.



18 May 2018

Sanoosa will be present at the Bio 2018 International Convention in Boston, MA, on June 4-7, 2018.  Sanoosa has developed a small molecule drug discovery & design platform that utilises its proprietary forecast-software to replace most of wet chemistry. Our technology comprises agile process structures and is focused on difficult to drug disease targets, like protein-protein interactions and protein surfaces. Sanoosa’s Founders will meet interested partners and potential collaborators at several one-on-one meetings in Boston.


25 March 2018

Sanoosa is collaborating with JATTECHNOLOGY to develop enhanced analysis tools for drug design applications.  As part of our support for the research community JATTECHNOLOGY and Sanoosa today deposited LigandViewer for macOS to the Mac App Store


20 September 2017

Working closely with a large pharma partner, Sanoosa received promising test results for Sanoosa’s Nav1.7 ion-channel inhibitor program and for another undisclosed target. The results for Nav1.7 delivered a novel scaffold which is now the basis to computationally design compounds for Nav1.7 inhibitors with higher specificity and selectivity.


16 May 2017

Changing Habits Pty Ltd has launched Sanoosa’s products for preventing inflammation  and for preventing hypercholesterolemia  into the Australian market. Concurrently, Changing Habits makes the products also available to its overseas customers. 


16 May 2017

A NATURAL APPROACH - MERGING SCIENCE & NATURE: Changing Habits / Sanoosa interview on disease prevention.


23 November 2016

Sanoosa Pty Ltd. enters a licensing agreement with Sunshine Coast /Australia based Changing Habits Pty Ltd to commercialize Sanoosa’s products for preventing inflammation and for preventing hypercholesterolemia .

Selected Publications:

 

  • First small molecule protein-protein interaction inhibitor to prevent PSCK9 binding to LDL receptor:   WO2018165718A1, Treutlein HR, Zeng J, Dixon I, James I, Palmer JT, Heterocyclic inhibitors of PCSK9. Patent published 20/09/2018.
  • Palmer JT; Lambert G; Treutlein HR; et al., “A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove”, Bioorganic & Medicinal Chemistry, Bioorganic & Medicinal Chemistry 28 (2020), 115344. https://doi.org/10.1016/j.bmc.2020.115344
  • Currier MA, Stehn JR, Swain A, …, Treutlein HR, et al. Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy With Microtubule Drugs. Molecular Cancer Therapeutics. May 2017. doi:10.1158/1535-7163.MCT-16-0873.
  • Stehn JR, Haass NK, Bonello T, Desouza M, Kottyan G, Treutlein HR, et al. A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells. Cancer Research. 2013 Aug 15;73(16):5169–82. 
  • Burns CJ, Bourke DG, Andrau L, Xianyong Bu, Charman SA, Donohue AC, Fantino E, Farrugia M, Feutrill JT,  Joffe M, Kling MR, Kurek M, Nero TL, Nguyen T, Palmer JT, Phillips I, Shackleford DM, Sikanyika H, Styles M, Su S, Treutlein HR, Zeng J, Wilks AF, Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorganic & Medicinal Chemistry Letters, 2009. 
  • First paper on the successful design of a protein-protein interaction inhibitor: Zeng J, Vuong-Nhen T, Zorzet A, Catimel B, Nice E, Burgess AW, Treutlein HR, Protein Engineering 14 (2001) 39, “Computational combinatorial design of short peptides that interfere with Ras-Raf association in vitro”.
  • This paper describes our early version of the MFMD method: Zeng J, Treutlein HR, A method for computational combinatorial peptide design of inhibitors of Ras. Protein Engineering 12, 457-468, 1999. 
  • Groenen LC, Walker F, Burgess AW, Treutlein HR. A Model for the Activation of the Epidermal Growth Factor Receptor Kinase: Involvement of an Asymmetric Dimer? Biochemistry 36 (13), 3826-3836, 1997. 
  • Treutlein HR, Schulten K, Brunger AT, Karplus M, Deisenhofer J, Michel H. Chromophore-protein interactions and the function of the photosynthetic reaction center: A molecular dynamics study, PNAS 89, 75-79, 1992.
  • Treutlein HR, Lemmon MA, Engelman DM, Brunger AT. The Glycophorin A transmembrane domain dimer: Sequence-specific propensity for a right-handed supercoil of helices.  Biochemistry 31, 12726-12733, 1992.


A complete list is available from Herbert's ORCID site: orcid.org/0000-0001-5553-5553

This website makes use of cookies. Please see our privacy policy for details.

This website makes use of cookies. Please see our privacy policy for details.

OK